Role of Serum Regucalcin in Diagnosis of HCC
Conditions
Brief summary
Although the diagnosis and therapy of HCC have being improved, the poor prognosis still remains. To reduce the mortality and improve the effectiveness of diagnosis and therapy, it is important to detect the protein biomarkers which are associated with HCC tumor progression and may be useful as potential diagnosis or therapeutic targets. SMP30 (senescence marker protein 30)(serum regucalcin), which we have previously identified from Guangxi HCC cDNA expression library by the SEREX approach, is one of the hepatocellular carcinoma associated antigens \[4\] Serum antibody response to SMP30 in various patients using the methods of Western-blot and ELISA and showed that antibody to SMP30 existed mainly in HCC patients (39.8%), especially in the one with alpha-fetoprotein (AFP) negative
Interventions
DIAGNOSTIC_TESTserum regucalcin antibody
serum regucalcin antibody
Sponsors
Mansoura University
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Newly diagnosed cases of HCC (be based on NCCN guidelines triphasic CT and AFP or liver biopsy) 2. Adult patients 3. Both genders are eligible. 4. Informed consent obtained from subject or subject's legal representative
Exclusion criteria
1. Patient with other malignancies. 2. Patients with advanced comorbidities except for renal failure. 3. Prior chemotherapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| serum regucalcin in HCC patients | 1-12-2016 to 1-12-2017 | This work aims to assess serum regucalcin antibodies level using ELISA in HCC patients to: * evaluate its potential role as biomarker in diagnosis. * evaluate potential associations of the presence of serum regucalcin antibody with HCC patients' clinico-epidemiological parameters. |
Countries
Egypt
Outcome results
None listed